CLONING AND CHARACTERIZATION OF THE HEPATITIS G VIRUS

美国国立卫生研究院和社区输血相关性肝炎的研究 疾控中心获得的数据显示，观察到的肝炎病例中有10%-20%可以 未被已知的肝炎病毒：甲型肝炎病毒、丙型肝炎病毒、HDV和 混合动力车。调查是否存在其他一个或多个代理 在人类肝炎方面，在以下部门之间建立了CRADA NIH输血医学公司，Genelabs Technologies，Inc.，加利福尼亚州埃默里维尔， 和疾控中心。可疑的临床材料被送到Genelabs，他们是 序列无关单链逆转录法扩增 利用GT1表达技术扩增并克隆到大肠杆菌中 向量。一个独特的克隆被鉴定出来，这对基因库来说是新的 通过杂交检测外源基因。该毒剂可以从 克隆源，并被证明是一种有别于其他病毒的黄病毒 那个家庭的成员。它与丙型肝炎病毒有大约25%的同源性。一种聚合酶链式反应 建立了检测方法，筛选了临床资料。代理， 暂定为HGV，约占输血的20% 以及与之前无关的社区相关性肝炎 公认的特工。HGV已被证明会导致急性和慢性 肝炎。在1-2%的献血者中发现了这种病毒，并已被证明是 输血--通过有关联的供受者样本传播。它看起来也 在某些肝炎相关再生障碍性疾病中起到致病作用 贫血。

Studies of transfusion-associated hepatitis at NIH and of community- acquired at CDC indicated that 10%-20% of observed hepatitis cases could not be accounted for by the known hepatitis viruses: HAV, HCV, HDV, and HEV. To investigate the existence of an additional agent or agents of human hepatitis, a CRADA was established between the Department of Transfusion Medicine, NIH, Genelabs Technologies, Inc., Emeryville, CA, and CDC. Suspect clinical materials were sent to Genelabs, and they were amplified following reverse transcription by Sequence Independent Single Primer Amplication and then cloned into E. Coli using a gt1 expression vector. A unique clone was identified that was novel to the gene bank and exogenous by hybridization assays. The agent could be recovered from the cloning source and was shown to be a flavivirus distinct from other members of that family. It had approximately 25% homology with HCV. A PCR assay was developed and clinical materials screened. The agent, tentatively designated HGV, accounts for approximately 20% of transfusion and community-associated hepatitis that is unrelated to previously recognized agents. HGV has been shown to cause acute and chronic hepatitis. It is found in 1-2% of blood donors and has been proven to be transfusion-transmitted by linked donor-recipient samples. It appears also to be the causative agent on some cases of hepatitis-associated aplastic anemia.